drugset / Trial / NCT07425899

A Phase 1 Study of the Safety and How the Body Processes ABBV-722 and Upadacitinib After Multiple Oral Doses in Healthy Adult Participants

NCT07425899

Phase 1 Recruiting 32 enrolled AbbVie
Non-randomizedSequentialOpen-labelTreatment

Summary

This is a Phase 1 study to investigate safety and pharmacokinetics of ABBV-722 and Upadacitinib following multiple oral doses in healthy adult participants.

Timeline

Start
2026-02-26
Primary completion
2026-08
Completion
2026-08

Drugs

EvaluationDrugModalityDoseRoute
Subject ABBV-722 Unknown Oral
Subject Upadacitinib Small molecule Oral

Indications

No indication recorded.